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Abstract
Background: In Duchenne muscular dystrophy (DMD), DYSTROPHIN deficiency exposes myofibers to repeated
cycles of contraction/degeneration, ultimately leading to muscle loss and replacement by fibrotic tissue. DMD
pathology is typically exacerbated by excessive secretion of TGFβ and consequent accumulation of pro-fibrotic
components of the extra-cellular matrix (ECM), which in turn impairs compensatory regeneration and complicates
the efficacy of therapeutic strategies. It is currently unclear whether DMD skeletal muscle fibers directly contribute
to excessive activation of TGFβ. Development of skeletal myofibers from DMD patient-derived induced pluripotent
stem cells (iPSC), as an “in dish” model of disease, can be exploited to determine the myofiber contribution to
pathogenic TGFβ signaling in DMD and might provide a screening platform for the identification of anti-fibrotic
interventions in DMD.
Methods: We describe a rapid and efficient method for the generation of contractile human skeletal muscle cells
from DMD patient-derived hiPSC, based on the inducible expression of MyoD and BAF60C (encoded by SMARCD3
gene), using an enhanced version of piggyBac (epB) transposone vectors. DMD iPSC-derived myotubes were tested
as an “in dish” disease model and exposed to environmental and mechanical cues that recapitulate salient
pathological features of DMD.
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Results: We show that DMD iPSC-derived myotubes exhibit a constitutive activation of TGFβ-SMAD2/3 signaling.
High-content screening (HCS)-based quantification of nuclear phosphorylated SMAD2/3 signal revealed that DMD
iPSC-derived myotubes also exhibit increased activation of the TGFβ-SMAD2/3 signaling following exposure to
either recombinant TGFβ or electrical pacing-induced contraction.
Conclusions: Acute conversion of DMD patient-derived iPSC into skeletal muscles, by the ectopic expression of
MyoD and BAF60C, provides a rapid and reliable protocol for an “in dish” DMD model that recapitulates key
pathogenic features of disease pathology, such as the constitutive activation of the TGFβ/SMAD signaling as well as
the deregulated response to pathogenic stimuli, e.g., ECM-derived signals or mechanical cues. Thus, this model is
suitable for the identification of new therapeutic targets in DMD patient-specific muscles.
Keywords: Duchenne muscular dystrophy, iPSC, TGFβ, pSMAD
Background
The identification of an effective treatment for muscular
dystrophies requires reliable preclinical models of dis-
ease. In the case of Duchenne muscular dystrophy
(DMD), the dystrophin-deficient mice (mdx mice) have
provided a valuable model to study certain common as-
pects of the disease [1], but the model is unfortunately
not informative on patient-specific pathological features
that could only be appreciated by using “in dish” disease
models from human patient-derived induced pluripotent
stem cells (iPSC).
An essential pre-requisite for “in dish” models of DMD
suitable for preclinical studies is the generation of an abun-
dant, homogenous, and expandable population of patient-
derived skeletal muscle cells. Although many protocols of
DMD patient iPSC-derived skeletal muscles have been de-
veloped in the last years, the large majority of them require
very long culture time (often over 30–40 days), as they are
based on the sequential action of developmental cues [2–
5] or sorting of specific populations generated by direct
conversion via transgenic expression (i.e., Pax3 or Pax7) in
iPSC-derived mesodermal progenies [5–8]. An alternative
approach is provided by the acute conversion of DMD
patient-derived iPSC into skeletal muscles by ectopic
expression of MyoD in differentiating human embryonic
stem cells (hESC) and iPSC that have already undergone
mesodermal or mesenchymal transition [7, 9–11]. How-
ever, while MyoD-mediated conversion of somatic cells
into skeletal muscle cells has been described about 30 years
ago [12, 13], the extension of this technique to iPSC is
complicated by the reported resistance of embryonic stem
cells (ESC) to MyoD-mediated activation of skeletal myo-
genesis [14]. We have shown that the SWI/SNF compo-
nent BAF60C (encoded by SMARCD3) is required for
MyoD-mediated activation of skeletal muscle genes [15],
and its absence confers to hESC resistance to MYOD-
mediated myogenic conversion [14]. Delivery of BAF60C
in hESCs enables MyoD-mediated myogenic conversion
and formation of tri-dimensional contractile structures
(myospheres), functionally resembling miniaturized skeletal
muscles [14]. Nevertheless, it is currently unclear whether
BAF60C is also required for MYOD-mediated generation
of skeletal muscles from hiPSC and in particular for the es-
tablishment of an “in dish model” of DMD using patient-
derived hiPSC.
Here, we provide a faster, scalable, and reproducible
method to generate skeletal muscle cells directly from
human iPSC, suitable for disease modeling. To this pur-
pose, we used an enhanced version of piggyBac (epB)
transposable vectors and epB MyoD [16] that increase
transposition efficiency in human pluripotent stem cells.
Transgene expression was kept under a TET transactiva-
tor gene control, in order to achieve inducible expression
of MYOD and BAF60C in hESC and iPSC and to allow a
straightforward and rapid myogenic differentiation.
We exploited our method to derive skeletal muscle
cells from control and DMD iPSC, as an “in dish” model
of DMD pathogenesis. We show that constitutive and
inducible deregulation of TGFβ-SMAD2/3 pro-fibrotic
network—a key component of DMD pathogenesis [3,
17–19]—is recapitulated in our system and can be used
to screen for compounds with therapeutic potential in
DMD.
Results
Direct generation of skeletal muscle cells from hiPSC
using inducible MyoD and BAF60C enhanced piggyBac
vectors
We generated homogeneous cultures of human skeletal
myotubes from DMD (or control) patient-derived iPSC,
by acute conversion via ectopic expression of MyoD and
BAF60C. We delivered into our iPSC cultures the epB
transposon vectors for MyoD and BAF60C by electro-
poration and subsequent selection for BAF60C and
MyoD vector-containing cells (Fig. 1a) to generate stable
cell lines that could differentiate into skeletal myoblasts
by sequential exposure to different culture conditions.
At day 0 (d0), induction of the transgenes was achieved
by addition for 24 h of doxycycline (doxy) at 200 ng/ml
in pluripotent cells maintained in the hESC culture
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medium (expressing pluripotent markers such as OCT4)
(Fig. 1b). At day 1 (d1), cells were dissociated in single
cells and plated at 25 k/cm2 in the growth medium
(GM) for 2 days in the presence of doxy. At day 3 (d3),
cells were placed in the differentiation medium (DM)
that contains N2 supplement, which was shown to
Fig. 1 Generation of stable hESC and iPSC lines and myogenic differentiation protocol. a Top: Scheme of inducible MyoD and Baf60c expression
vectors generated using the enhanced version of piggyback (ePB) as described [16]. Puro, puromycin resistance; Bsd, blasticidin resistance; UbcP,
ubiquitin C constitutive promoter; TRE, Tet-responsive element. Bottom: Protocol for myogenic differentiation of puromycin and blasticidin-
resistant cells (hESC or iPSCBM) obtained after stable integration of the ePB vectors. Differentiation protocol starting from hESCBM and iPSCBM.
Transgene expression is achieved by the addition of doxycycline (doxy, red line) in the hES medium for 24 h. Myogenic conversion is then
triggered by switch to the proliferation medium (GM) at day 1 and to the differentiation medium (DM) at day 3. b Representative
immunofluorescence images of hESCBM or iPSCBM at each step of the protocol. iPSCBM at the pluripotent stages are marked by OCT4, followed by
the expression of BAF60C (green) and MyoD (red) upon doxy induction at d1 and the appearance of MYOGENIN at d3. At day 7, myotubes are
visible and express the marker of terminal differentiation myosin heavy chain (MYHC, green) containing MYOGENIN-positive nuclei (Myog, red).
Nuclei are counterstained with DAPI. Scale bar, 50 μm. c Relative gene expression by qRT-PCR of the indicated genes in a time course. Data are
represented as average ± SEM (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 (unpaired Student’s t test). d Quantification of markers of myogenic
conversion efficiency (e.g., MyoD, Myog, MyHC) in MyoD/BAF60C expressing hESC and hiPSC after 7 days of culture in DM (as average ± SEM)
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improve myogenic differentiation [2] (Fig. 1b). Upon in-
duction of BAF60C and MyoD (Fig. 1b, c), iPSC sequen-
tially expressed early (myogenin) and late (muscle creatine
kinase; CKM) myogenic markers (Fig. 1c). The activation of
the myogenic program was accompanied by the downregu-
lation of pluripotency genes (OCT4) and the mesodermal
marker Brachyury T (T) (Fig. 1c), consistent with the ability
of MyoD to “erase” the cell of origin transcriptome profile,
upon commitment to the myogenic lineage [20]. Overall,
by day 7, around 60 to 70% of the BAF60C/MyoD-express-
ing hiPSC (iPSCBM) could phenotypically differentiate into
multinucleated skeletal myotubes (Fig. 1d). Consistently,
qRT-qPCR analysis detected induction of markers of ter-
minal differentiation, such as MYOGENIN (MYOG) and
Creatine Kinase, Muscle (CKM) in these cultures (Fig. 1b,
c), and immunofluorescence revealed the simultaneous ex-
pression of MYOG and Myosin Heavy Chain (MyHC) pro-
teins in myotubes. We could also observe remaining
mononucleated MYOG-positive cells outside the myotubes,
indicating that more than 90% of the cells entered the myo-
genic program. By contrast, the absence of Pax7-positive
cells indicates that this experimental system is not suitable
for the study of reserve muscle stem cells.
Generation of skeletal muscles from DMD patient-derived
hiPSC leads to aberrant activation of TGFβ1-SMAD
signaling
We exploited the strategy described above to directly
generate skeletal myotubes from DMD patient-derived
hiPSC, as compared to their healthy counterpart. We
used two different human healthy (control) and DMD
hiPSC lines as described in the “Material and methods”
section. DMD hiPSC lines carry different types of muta-
tions in the DYSTROPHIN gene: a stop codon mutation
at exon 59 (DMD iPSCex59X) that we used for the major-
ity of the experiments shown in the main figures, and
exon 45 deletion (DMD iPSCex45del).
To induce differentiation of DMD iPSC-derived myo-
blasts, we cultured them at high confluence, as we observed
that low confluence would partially affect their myogenic
potential (data not shown), possibly because of the inhibi-
tory effect of TGFβ on myoblast differentiation at low con-
fluence. Under these conditions, DMD iPSCBM-derived
myotubes were phenotypically indistinguishable from con-
trol iPSCBM-derived myotubes and expressed similar levels
of myogenic markers (Fig. 2a, b, S1 and S2A). Consistently,
DYSTROPHIN deficiency did not impair the ability of
DMD-derived primary myoblasts to differentiate into
MyHC-expressing multinucleated myotubes (Fig. 2a, b)
(this issue is further discussed in the “Discussion” section).
Likewise, siRNA downregulation of DYSTROPHIN did not
compromise the formation of multinucleated myotubes
from MyoD-converted human IMR90 fibroblasts (Fig. 2a,
b). Of note, in all cases, DYSTROPHIN-deficient myotubes
invariably exhibited constitutive activation of TGFβ signal-
ing, as shown by the increased nuclear signal of the TGFβ
nuclear effectors phospho-SMAD2/3 (using an anti-
pSMAD3 antibody) (Fig. 2c, d, S2B) and the increased ex-
pression of TGFβ1 itself (Fig. 2e).
High sensitivity to TGFβ1-SMAD signaling activation in
skeletal muscle generated from DMD patient-derived
hiPSC
We further investigated whether skeletal muscles gener-
ated from DMD human patient-derived iPSC could be
more susceptible to the activation of SMAD2/3 signaling
as compared to their normal counterpart, when chal-
lenged with the exposure to recombinant TGFβ1. We
employed the high-content screening (HCS) platform to
detect aberrant SMAD2/3 signaling (Fig. 3a). Myogenic
differentiation was achieved according to the protocol il-
lustrated in Fig. 1 (see details in the “Materials and
methods” section). At d7, myotubes were treated with
TGFβ, and the analysis of nuclear pSMAD3 was per-
formed by immunostaining at different time points from
the treatment. Nuclear pSMAD3 was quantified using
ImageXpress Micro High Content Screening System,
and MetaXpress Analysis software (Molecular Devices),
which allows accurate quantification of the signal thanks
to a “mask-assisted” selection of nuclear signal, defined
by the tuning of specific parameters, such as signal back-
ground and size (Fig. S3). This quantification results in a
very accurate background subtraction that cannot be
reached by the common software analysis. We used two
different antibodies that recognize pSMAD2/3 as a read-
out of the activation of TGFβ-SMAD signaling in DMD
myotubes, to support the reproducibility of this assay
(Fig. S3). Exposure to recombinant TGFβ (20 ng/ml) in
the culture medium for 5 h and 24 h led to nuclear accu-
mulation of pSMAD2/3 quantified as a percentage of
pSMAD3 fluorescence at 24-h treatment in both DMD
and control hiPSC-derived myotubes. However, DMD
hiPSC-derived myotubes showed a 2-fold increase in nu-
clear accumulation of pSMAD2/3 in response to TGFβ,
as compared to control myotubes (Fig. 3b, c, S2B). Like-
wise, DMD hiPSC-derived myotubes showed increased
levels of TGFβ1 transcripts 24 h after the exposure to re-
combinant TGFβ (Fig. 3d). To rule out the possibility
that higher TGFβ response observed in DMD myotubes
was due the higher basal levels of pSMAD2/3 (Fig. 2c–
e), we pre-treated control and DMD hiPSC-derived
myotubes with the SB-431542 ALK5 (TGFβRI) inhibitor
24 h prior to the exposure to TGFβ (Fig. 3e). The inhib-
ition of autocrine activation of TGFβ pathway was re-
vealed by the drastic reduction of the nuclear pSMAD3
signal in DMD myotubes (S4A). TGFβ response was also
monitored by measuring TGFβ1 expression with RT-
qPCR, which showed a delayed but greater response to
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TGFβ in DMD myotubes pre-treated with SB (5-fold in
DMD vs. control myotubes) (Fig. 3e).
This evidence demonstrates that DMD myotubes ex-
hibit an aberrant activation of the TGFβ pathway, in
addition to the constitutive activation, implying that auto-
crine secretion of TFGβ is not the sole source of over-
activation of pro-fibrotic response in DMD myotubes.
Moreover, we tested the suitability of the system as a cell-
based assay for drug screenings by using pharmacological
inhibition of pSMAD. For this purpose, we used the
“dual-SMAD” inhibitor cocktail reported in Choi et al. [3]
composed by LDN193189 and SB431542 and we evalu-
ated the dose-response effect by HCS. We used the
cocktail at increasing concentrations (Fig. S4B) and ob-
served a gradual decrease in the nuclear pSMAD2/3 signal
in myotubes, as compared to control cells treated with the
vehicle (DMSO), indicating a dose-dependent response to
pharmacological inhibition of pSMAD (Fig. S4B-C).
Electrical pacing-induced contractions trigger TGFβ
activation and exacerbate the fibrotic pathway in DMD
muscles
We further assessed whether our “in dish” model of
DMD could be exploited to study TGFβ response and
activation of pro-fibrotic process signaling in myotubes
within a more physiological context, by evoking myotube
Fig. 2 Evaluation of the myogenic potential of DMD iPSCBM and activation status of TGFβ signaling. a Immunofluorescence for MyHC, performed
in cells differentiated into myotubes. Control and DMD iPSC (ex59X), expressing inducible ePB vectors for MyoD and BAF60C (iPSCBM), were
differentiated according to the protocol described in Fig. 1. Control and DMD human myoblasts were differentiated by medium switch; IMR90
cells, previously nucleofected with inducible ePB vector for MyoD (IMR90MyoD), were differentiated by medium switch (see the “Materials and
methods” section for details). To monitor the effect of the lack of DYSTROPHIN during myogenic conversion in IMR90, cells were transfected both
in GM and DM conditions with siRNAs for DYSTROPHIN (siDMD) or a scrambled sequence (siScr). The level of DYSTROPHIN downregulation is
shown on the left. b Myogenic index (bottom graph) was calculated by immunofluorescence staining, as the percentage of nuclei within MyHC-
expressing myotubes. c Immunofluorescence for pSMAD in iPSCBM, human myoblasts, and IMR90MyoD-derived myotubes. Nuclei were visualized
by DAPI. Scale bar, 50 μm. d The percentage of pSMAD3-positive cells was calculated counting 10 fields and using the same exposure parameters
among the samples. e TGFβ1 relative expression monitored in all the cells. The expression levels are shown as relative to the control or siSCr.
Data are represented as average ± SEM (n = 3) *p < 0.05; **p < 0.01; ***p < 0.001 (unpaired Student’s t test)
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contraction with prolonged time of electrical pacing. We
sought to use this system to recapitulate the key patho-
genic mechanism of DMD, such as the biomechanical
stress-dependent inflammatory and fibrotic response.
To this purpose, we used the state-of-the-art pacing
system xCELLigence® RTCA CardioECR System (pro-
vided by Acea Biosciences), which allows simultaneous
measurement of myocytes contractility and electrophysiology.
This platform, originally designed for cardiomyocytes,
was adapted to cell types competent to respond to
electrical pacing (i.e., myotubes) and allowed the
synchronization of contractions. While cardiomyocytes
spontaneously contract, iPSC-derived myotubes did
not display this feature (although we could detect
sporadic spontaneous contractions). For this reason,
we electrically stimulated DMD and control iPSC-
Fig. 3 Employment of control and DMD iPSC in high-content screening setting for the assessment of TGFβ response. a Schematic representation
of the protocol used for HCS. To ensure higher control over cell number and reproducibility, cells have to be dissociated in single cells before
doxycycline treatment. Cells are plated in Matrigel-coated 384-optical well plates, fixed, and stained and then analyzed by MetaXpress Analysis
software. b Representative immunostaining of control and DMD iPSC (ex59X)-derived myotubes, stained for pSMAD3 in normal condition and
upon treatment with TGFβ (20 ng/ml) and c quantification of the percentage of pSMAD3 fluorescence obtained by MetaXpress Image analysis
software, setting background and size parameters as described in the “Materials and methods” section. Data are expressed as fold change. d
Gene expression of TGFβ1 in control and DMD iPSC-derived myotubes expressed as fold induction of TGFβ-treated versus untreated cells. e Gene
expression of TGFβ1 mRNA expression in control and DMD iPSC-derived myotubes pre-treated with TGFβR1 inhibitor (SB-431542 (10 μM)),
expressed as fold induction of TGFβ-treated versus untreated cells. All data are represented as average ± SEM (n = 3). *p < 0.05; **p < 0.01; ***p <
0.001 (unpaired Student’s t test)
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derived myotubes for 12 h, under different parameters.
We could reproducibly detect myotube contractions by
pacing the cells for a prolonged time of 12 h at 1 Hz, with
0.5 ms, and recorded contraction events in all the repli-
cates (Fig. 4a), as shown in the graphs (red = control,
green = DMD, X axis = time, Y axis = cell index). The
contraction signals were compared to those of control-
undifferentiated iPSC, which are not excitable by electrical
pacing. Accumulation of pSMAD2/3 was monitored by
immunofluorescence and quantified using Image J soft-
ware and values are reported as fold change of pSMAD3
fluorescence upon pacing, as compared to control non-
paced cells (Fig. 4b). Again, we detected pSMAD3 nuclear
accumulation following electrical pacing at a greater ex-
tent in DMD iPSCex59X-derived myotubes (3.5 fold) as
well as in DMD iPSCex45del, when compared to control
myotubes (2.3 fold), indicating that pacing-induced
contraction is sufficient to trigger an exacerbated activa-
tion of TGFβ/SMAD signaling in DMD myotubes (Fig. 4b
and S2C). We next monitored the activation of pro-
fibrotic genes (TGFB1, TGFB2, IL6, and CTGF) in control
and DMD iPSC-derived myotubes post-contraction, by
evaluating their expression profile right after 12 h of
pacing (paced) and after 12 h release from pacing (paced +
release) and compared this profile to the non-paced myo-
tubes (control) (Fig. 4c). A greater and persistent increase
in the expression of fibrotic genes was observed in elec-
trically paced DMD myotubes, as compared to control
myotubes (Fig. 4c). The activation and persistence of pro-
fibrotic gene activation were also evaluated and validated
in human immortalized myoblasts induced to differentiate
and then paced using the same conditions of pacing ap-
plied for iPSC-derived myotubes (Fig. S5). Of note, we
could observe that in control iPSC-derived myotubes, the
Fig. 4 Pacing-induced contraction in iPSC-derived myotubes and activation of pSMAD signaling. a xCELLigence® RTCA CardioECR System (Acea
Biosciences) was used to pace the cells electrically for 12 h, using 1 Hz, 0.5 ms pulse length, and 2.2 volt intensity. Contraction profiles are shown
for each cell line including the negative control (non-excitable cell iPSC). The Y axis represents cell index and the X axis represents time. The
contraction profiles indicate that iPSC-derived myotubes can contract after pacing. b Immunofluorescence for pSMAD3 in control iPSC- and DMD
iPSC (ex59X)-derived myotubes in control conditions (non-paced) or after 12 h pacing and quantification of pSMAD3 accumulation, expressed as
a percentage of pSMAD fluorescence of paced versus non-paced cells. *p < 0.05; **p < 0.01; ***p < 0.001 (unpaired Student’s t test). c Activation of
pro-fibrotic genes (TGFβ1, TGFβ2, IL6, and CTGF) was monitored in control and DMD iPSC-derived myotubes after 12 h pacing (paced), after 12 h
release from pacing (paced + release) and compared to control not paced cells (Ctr). The conditions used allow to see a greater and persistent
fibrotic response in electrically paced DMD iPSC-derived myotubes as compared to control iPSC-derived myotubes. Data are represented as
average ± SEM (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001 (unpaired Student’s t test)
Caputo et al. Skeletal Muscle           (2020) 10:13 Page 7 of 11
electrical pacing did not result in a significant activation of
the TGFβ/SMAD pathway, as compared to chemically in-
duced TGFβ activation, unlike DMD-derived myotubes
(Fig. 4 and S5). This evidence suggests that, in our condi-
tions, electrical pacing could evoke contraction-dependent
pathogenic events typical of DMD muscles, such as sus-
ceptibility and consequently activation of TGFβ and pro-
fibrotic genes.
Discussion
The identification of the molecular mechanisms driving
hESC and disease-specific hiPSC differentiation into
multiple lineages is of key importance in regenerative
medicine. Besides the potential to generate patient-
specific cell populations for gene corrections and trans-
plantations, the availability of patient-derived iPSC pro-
vides the unprecedented opportunity to recapitulate the
disease in a dish and therefore to use it as a screening
platform to find new therapeutic targets involved in the
pathogenesis or novel compounds able to revert a dis-
ease phenotype.
Here, we report a fast, simple, and efficient method for
acute iPSC conversion into muscle cells based on the
use of transposon-based vectors encoding two key fac-
tors, MyoD and BAF60C, that guarantee a straightfor-
ward conversion of iPSC towards myogenic cells.
We show that this system is amenable to model DMD
and could be suitable for a cell-based high-content
screening-based drug discovery for DMD. Studies aimed
at the identification of nodal pathways implicated in DMD
development and disease progression downstream to
DYSTROPHIN have revealed that TGFβ triggered pro-
fibrotic network is invariably activated in DMD muscles,
irrespective of the DYSTROPHIN mutation [3, 18]. In par-
ticular, nuclear accumulation of the active, phosphorylated
form of SMAD 2/3 (phospo-SMAD2/3) has been observed
in DMD [3]. Indeed, increasing evidence points to fibrosis
as a key pathogenic determinant of DMD progression, be-
ing responsible for the loss of contractile fibers, but also
contributing to the progressive impairment of the regener-
ation ability of DMD muscles [19, 21, 22]. As such, target-
ing pathogenic events downstream of DYSTROPHIN, as
the molecular networks implicated in the development of
fibrosis and related maladaptive responses, are emerging
as promising therapeutic interventions that can effectively
counteract disease progression in DMD patients [23].
Our protocol allows efficient myogenic conversion of
both control and DMD iPSCs, and we show that DMD
iPSC-derived myotubes display an activated SMAD signal-
ing in unperturbed conditions. Moreover, DMD iPSC-
derived myotubes also exhibit an exacerbated response to
TGFβ that can be reliably quantified by pSMAD nuclear
accumulation either in response to recombinant TGFβ or
upon electrophysiological stimulation. The system reported
herein has therefore the potential to be used as a screening
platform for the discovery of compounds that target
TGFβ-activated responses in dystrophic muscles.
In a recent study, Choi et al. showed that DMD
hiPSC-derived muscles, irrespectively of the mutation,
exhibit higher nuclear pSMAD2/3 signal compared to
controls and that aberrant SMAD activity was associated
with impaired fusion of DMD hiPSC-derived myoblasts,
since anti-TGFβ compounds that lowered nuclear
pSMAD2/3 levels could also correct the fusion defects.
We did not observe an impaired differentiation into
multinucleated myotubes in DYSTROPHIN deficient
myoblasts generated from DMD hiPSC, from DMD
myoblasts, or from MyoD-converted human fibroblasts.
While this discrepancy is likely due to the different pro-
tocols used (transcription factors vs. small molecules)
for the induction of skeletal myogenesis in hiPSC, the
similar ability to differentiate into myotubes exhibited by
DMD and control myoblasts indicate that additional pa-
rameters could account for this discrepancy. Among
them, we suggest that high cell confluence could be a
key determinant for tolerance to TGFβ-mediated inhib-
ition of differentiation, as we found that low confluence
compromises the differentiation ability of DMD hiPSC-
derived myoblasts. Regardless, we observed that inhib-
ition of the TGFβ/BMP4 pathway could further improve
the myogenic potential of both control and DMD iPSC.
This is consistent with the reported lower fusion index
of iPSC-derived myoblasts, as compared to adult primary
human myoblasts, due to elevated TGFβ levels in the
iPSC cultures [3, 24].
The importance of having generating contractile myo-
tubes from patient-derived iPSC resides in their potential
exploitation for “in dish” model of DMD, by performing
functional analysis of their biomechanical properties. We
found that both control and DMD iPSC-derived myotubes
responded to contractile stimuli, and we were able to re-
capitulate the fibrotic pathological outcome of DMD, as
revealed by a pSMAD2/3 accumulation in the nucleus and
by the higher and persistent activation of downstream
pro-fibrotic target genes. Overall, the method proposed to
generate muscle cells from patient-specific iPSC is par-
ticularly suitable to study aberrant activation of patho-
genic pathways (i.e., TGFβ and other fibrotic signaling) in
DMD muscles and can be exploited to investigate the mo-
lecular basis of DMD and the identification of molecular
targets for interventions that counter the fibrogenic activ-
ity of DMD muscles.
In this regard, it is worth noting that pacing-induced
contraction in vitro elicited upregulation of IL6 tran-
scripts only in cultures of DMD myotubes, with only a
modest increase in IL6 observed in control myotubes.
While this seems in apparent conflict with previous
works reporting on IL6 release from muscles during
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exercise/physical activity [25], we argue that muscle con-
traction within the context of systemic exercise in vivo
or upon electrical stimuli in vitro differs on multiple pa-
rameters that might account for the different output of
IL6. Indeed, exercised muscles in vivo contain cell types
(i.e., macrophages, FAPs) that could contribute to the
output of IL6 secretion and that are not present in pure
cultures of iPSC-derived skeletal myotubes. Further-
more, pacing-induced contraction of iPSC-derived skel-
etal myotubes does not account for the complexity of
exercise-mediated contraction of skeletal muscles that
typically includes multiple rounds of contraction at dif-
ferent frequencies and is mediated by neuromuscular
junctions, which were not included in our in vitro sys-
tem. Finally, within the context of exercise, skeletal mus-
cles are exposed to systemic factors that are obviously
not present in cultures of iPSC-derived myotubes. While
we acknowledge that the absence of NMJ and systemic
factors currently represent a limitation in the interpret-
ation of data derived from “in dish” models of DMD, we
also note that an intrinsic advantage of our experimental
system with patient-derived cultures of myotubes is the
opportunity to study the specific effect of DYS-
TROPHIN deficiency on the transcriptional output from
skeletal myofibers, regardless of the complexity of the
systemic environment in vivo. This might help to under-
stand the primary molecular relationship between DYS-
TROPHIN deficiency and altered profiles of gene
expression in skeletal myofibers in response to contrac-
tion, in order to identify specific targets for the correc-
tion of the pathogenic transcription output in DMD
muscles. In this regard, our data provide the first evi-
dence that contraction stimulates IL-6 expression (as
well as the expression of other fibrogenic genes) in
DMD myotubes, but not in their control counterpart, re-
gardless of the influence of secondary events from non-
muscle cells (i.e., chronic inflammation, fibrosis) that are
typically observed in DMD patients.
Materials and methods
Cell lines
The human ES cells used are H9 (from the Stem Cell
Core), Control iPSC (iPSC-control) were obtained from
La Spada Lab (UCSD) from healthy patient’s fibroblasts
(IRB #130337ZF) or from Coriell (AG08C5). Duchenne
Muscular Dystrophy iPSC (iPSC-DMD) was obtained
from DMD patient’s fibroblasts (Coriell GM04619) car-
rying mutation in stop codon at 2905 of exon 59. iPSC
lines were generated by Sendai Virus reprogramming
(SBP Lake Nona). DMD iPSC (Coriell GM25313) carries
deletion at exon 45. Both hESC and iPSC were main-
tained and propagated as colonies in hES maintenance
medium mTeSR1 and passaged using ReLeSr (Stem Cell
Technologies) on Matrigel-coated wells (BD Bioscience).
IMR90 cells (obtained from Coriell) were cultured,
nucleofected, and differentiated as described [26]. siRNA
transfection was performed using siRNAs against a scram-
bled sequence (control) or DYSTROPHIN (DMD) (Dhar-
macon) at 20 nM concentration with RNAiMAX, first in
proliferating cells and then 1 h after differentiation.
Human control and DMD myoblasts (carrying deletion
of exons 45-52), obtained from AFM-MyoBank, were
cultured in Skeletal Muscle Cell Growth Medium Kit
(Promocell), and differentiation was induced by switch-
ing the medium to DMEM (Invitrogen) supplemented
with insulin (10 μg/ml). Recombinant human TGFβ1
(Peprotech) was used at 20 ng/ml. SB-431542 (Med-
ChemExpress) and LDN-193189 (Selleckchem) were
added for 24 h in cell media.
Plasmid construction and generation of stable cell lines
The epB-Puro-TT-mMyoD plasmid is described in Lenzi
et al. [16]. Briefly, the epB-Puro-TT-hBaf60c was ob-
tained through the subcloning of the FLAG-hBAF60c2
cDNA (from the pBMN-FlagBaf60c2 vector) into the
epB-Bsd-TT plasmid (Bsd = blasticidin resistance) [27].
Both vectors are endowed with a tetracycline-responsive
promoter (TRE) that drives the expression of the trans-
genes. MyoD construct contains the constitutive puro-
mycin resistance cassette fused to the rtTA (TET
transactivator) gene, whereas Baf60c construct contains
a Blasticidin resistance cassette fused to the rtTA.
The plasmids were transfected into the cells by elec-
troporation using the Neon Transfection System, follow-
ing the manufacturer’s instructions. epB-Puro-TT-
mMyoD, epB-Bsd-TT-hBaf60c, and the transposase were
transfected at the ration 2:2:1 respectively, using a total
of 5 μg of DNA for 1 × 106 cells. Selection was per-
formed using 1.5 μg/ml of Puromycin and 3 μg/ml of
Blasticidin at the same time.
Myogenic differentiation of hESC and iPSC
hESC or iPSC stably expressing MyoD and Baf60C indu-
cible transgenes (hESCBM or iPSCBM) were propagated
in mTeSR1 on Matrigel-coated wells. To induce myo-
genic differentiation starting from iPSC colonies, doxy-
cycline (200 ng/ml) was added in cells maintained in
mTeSR1 (day 0). After 24 h of treatment with doxycyc-
line (day 1), cells were dissociated as single cells using
TripLe and plated 25 k/cm2 in GM medium (knockout
DMEM (Invitrogen) supplemented with 1mM L-glutam-
ine, 20% knockout serum replacement medium (KOSR,
Invitrogen), 1 mM sodium pyruvate, 0.1 mM nonessen-
tial amino acids (NEAA, Invitrogen), 50 U/ml penicillin,
50 mg/ml streptomycin (Invitrogen), 0.1 mM beta-
mercaptoethanol (Invitrogen)) plus hES cell recovery
supplement (10 uM) (Stemgent) and doxycycline.
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On day 3, GM medium was switched to DM medium
(DMEM containing 2% Horse Serum and 1× ITS supple-
ment (SIGMA)) and doxycycline until day 7. To induce
myogenic differentiation starting from single cells,
hESCBM or iPSCBM were first dissociated into single
cells, plated at 15 k/cm2 density, and then exposed to
doxycycline in mTesR1 medium (d0).
Immunofluorescence
Cells grown on Matrigel-coated 384-well optical tissue
culture plates (Greiner Bio-One) were fixed with 4%PFA
for 15min at room temperature, and permeabilized in
0.5% Triton X-100 then blocked in 4%BSA (blocking buf-
fer) for 30min. Incubation with the primary antibodies
diluted in blocking buffer was performed overnight. The
antibodies used are as follows: anti-Myod (BD Bioscience,
554,130), anti-Myogenin (clone F5D, DSHB), anti-GFP
(Invitrogen, A11122), anti-Baf60c custom made, anti-
myosin heavy chain (MF20, DSHB), anti-pSMAD 2/3 (cs
#8828 s, Cell signaling) and anti-pSMAD3 (ab52903,
abcam), desmin, Ki67, and Fast MyHC (abcam). Alexa-
488 or 555 or 647 were used as secondary antibodies
(Invitrogen). Nuclei were counterstained with DAPI.
High-content imaging analyses were performed using an
automated fluorescent microscope with environmental
control (CO2, O2, and humidity) (ImageXpress Micro High
Content Screening System, Molecular Devices) and Image
analysis software (MetaXpress Analysis software and cus-
tom modules) for the quantification of the signal intensity
after staining for phospho-SMAD3 (pSMAD3). To assure
that signal accurately reflects the pSMAD3 levels in nuclei
of myotubes, we exploited a standard “mask-assisted” se-
lection of nuclear signal that has been optimized by select-
ing specific parameters, such as signal background and
size. The intensity of the signal detected in each of the
384-well plates is laser captured and quantified by MetaX-
press Analysis software or Image J software alternatively.
Gene expression analysis
Total RNA was isolated with TRIzol or RNease Micro
Kit (Qiagen) and retrotranscribed using reverse tran-
scription reagent (Applied Biosystems). qRT-PCR was
performed in a Mx3000P machine (Stratagene) using
SYBR Green Master Mix. Data were normalized to the
expression of GAPDH gene. Primers sequences are the
following (5′–3′): GAPDH (fw-AGCCGCATCTTCTT
TTGCGTCG; rev-CTTCTCCATGGTGGTGAAGACG),
mMyoD (fw-AATGGCTACGACACCGCCTACTA; rev-
AGATGCGCTCCACTATGCTGGACA), MYOG (fw-
AATGCAGCTCTCACAGCGCCTC; rev-TCAGCC
GTGAGCAGATGATCC), CKM (fw-TGGAGAAGCT
CTCTGTGGAAGCTC; rev-TCCGTCATGCTCTT
CAGAGGGTAGTA), BAF60C2 (fw-GCGCGCAAAG
CCACGAAA; rev-ATCCGGGCTCCAGACGGCATC),
OCT4 (fw-GACAGGGGGAGGGGAGGAGCTAGG;
rev-CTTCCCTCCAACCAGTTGCCCCAAAC), BRA-
CHYURYT (fw-TTGATGCAAAGGAAAGAAGTGA
TC; rev-AGGATGAGGATTTGCAGGTG), TGFB1 (fw-
GCCTGAGGCCGACTACTA; rev-CTGTGTGTAC
TCTGCTTGAACT), IL6 (fw-GGTACATCCTCGAC
GGCATCT; rev-GTGCCTCTTTGCTGCTTTCAC),
CTGF (fw-TGTGCACCGCCAAAGAT; rev-GCACGT
GCACTGGTACTT), and TGFB2 (fw-TGGTGAAAGC
AGAGTTCAGAG; rev-CGCTGGGTTGGAGA
TGTTAA).
Electrical pacing and recording
DMD and control iPSC expressing epB-BAF60C/MyoD
were seeded on 48 gold electrode wells and induced to
differentiate as previously described. At d10, electrical
pacing was initiated by applying a pulse train amplitudes
of f = 1 Hz, ton = 0.5 ms (pulse length), and Vapp = {2.2 V}
using xCELLigence® RTCA CardioECR (ACEA eBios-
ciences). Undifferentiated iPSC were used as a negative
control, being non-excitable cells.
Statistics
Statistical analyses were carried out using Excel or Prism
v8. Data are represented as mean ± SEM or mean ± SD
as described in the figure legend. Graphs are prepared
using Prism. Double tail t test was used for statistical
analysis, *p < 0.05, **p < 0.01, and ***p < 0.001.
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